Latest:
Our Move to an EHR
The initial capital outlay for transitioning to an EHR is not small. In fact, cost is one of the main reasons practices have been slow to adopt EHRs.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Lindsay Frazier, MD
Latest:
Dr. Fraizer Discusses the MaGIC Consortium
Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.
Lisa Astor
Latest:
CD22-Directed CAR T-cell Therapy Elicits High CR Rates in LBCL After CD19 Relapse
CD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.
Lisa Barbarotta, MSN, AOCNS, APRN-BCÂ
Latest:
Nurse-Driven Website Empowers Nurses to Improve Patient Care
Improving communication, building relationships, coordinating activities among units, and engaging staff members are not only ways to create a more positive working environment, they are critical for maintaining patient safety.
Lisa Butterfield, PhD
Latest:
Lisa Butterfield on SITC Immune Biomarkers Task Force
Lisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.
Lisa Giulino Roth, MD
Latest:
Dr. Roth on Treating AYA Patients With Hodgkin Lymphoma
Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.
Lisa H. Butterfield, PhD
Latest:
Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma
Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.
Lisa Miller
Latest:
Persistence Paved the Path of Discovery for an Immunotherapy Pioneer
Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.